NCT03905148View on ClinicalTrials.gov

Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

September 30, 2025

Study Completion Date

February 28, 2026

Conditions
Solid Tumor, Adult
Interventions
DRUG

Lifirafenib

RAF Dimer Inhibitor

DRUG

mirdametinib

MEK Inhibitor

Trial Locations (6)

2031

The Prince of Wales Private Hospital - Specialist Medical Randwick, Randwick

2148

Blacktown Cancer and Haematology Centre, Blacktown

3000

Peter MacCallum Cancer Centre, Melbourne

6009

Linear Clinical Research, Nedlands

77030

MD Anderson, Houston

90404

University of California Los Angeles, Santa Monica

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
collaborator

SpringWorks Therapeutics, Inc.

INDUSTRY

lead

BeiGene

INDUSTRY